Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Cangene Corporation Announces Workforce Reduction
Cangene Corporation announced that it will reduce its workforce from approximately 700 to 580 positions, representing a change of about 17% that includes the elimination of vacant positions. Cangene is providing affected employees with severance and outplacement services in keeping with its policies, local laws and regulations. The workforce reduction is believed to be a prudent and necessary step for the long term success of the Company.
Latest Developments for Cangene Corp
- Cangene Corp Announces FDA Approval Of Botulism Antitoxin
- Ipsen SA and Inspiration Biopharmaceuticals Inc Announce Closing of the IB1001 Sale to Cangene Corp
- Cangene Corp's VARIZIG Receives Food and Drug Administration Approval
- United States Food and Drug Administration Approves Cangene Corp's VARIZIG
Latest Key Developments in Pharmaceuticals
- Glenmark Pharmaceuticals Ltd Receives Final ANDA Approval For Riluzole Tablets, 50mg
- Valeant Pharmaceuticals International Inc's VPII Escrow Corp Announces Launch Of Private Offering Of Senior Notes
- Hubei Guangji Pharmaceutical Co Ltd to Acquires 35% Stake in Subsidiary
- Valeant Pharmaceuticals International Inc Prices Public Offering Of Common Shares
- Share this
- Link this
- Digg this
Follow Reuters